Approaches to multidrug resistance reversal

Bibliography

• BIEDLER JL, RIEHM H: Cellular resistance to actinomy-cin D in Chinese hamster cells in vitro: cross resis-tance, radioautographic and cytogenetic studies. Cancer Res. (1970) 30:1174–1184.
   PubMed Web of Science ®Google Scholar
• DANO K: Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta (1973) 323:466–483.
   PubMed Web of Science ®Google Scholar
• CHEN C, CHIN JE, UEDA K eta].: Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 47:381–389.
   Google Scholar
• GERLACH JH, ENDICOTT JA, JURANKA PF et al.: Homol-ogy between P-glycoprotein and a bacterial haemo-lysin transport protein suggests a model for multidrug resistance. Nature (1986) 324:485–489.
   PubMed Web of Science ®Google Scholar
• ENDICOTT JA, LING V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann. Rev. Biochem. (1989) 58:137–171.
   PubMed Web of Science ®Google Scholar
• GOTTESMAN MM, PASTAN I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. (1993) 62:385–427.
   PubMed Web of Science ®Google Scholar
• THIEBAUT F, TSURUO T, HAMADA H eta].: Cellular local-ization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. ScL USA (1987) 84:7735–7738.
   Google Scholar
• CORDON-CARDO C, O'BRIEN JP, CASALS D et al.: Multidrug-resistance gene (P-glycoprotein) is ex-pressed by endothelial cells at blood-brain barrier sites. Proc. Natl Acad. Sci. USA (1989) 86:695–698.
   Google Scholar
• VAN HELVOORT A, SMITH AJ, SPRONG H et al: MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell (1996) 87:507–517.
   PubMed Web of Science ®Google Scholar
• TSURUO T, IIDA H, TSUKAGOSHI S, SAKURAI Y: Over-coming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of yin-cristine and vinblastine by verapamil. Cancer Res. (1981) 41:1967–1972.
   PubMed Web of Science ®Google Scholar
• GEORGES E, SHAROM FJ, LING V: Multidrug resistance and chemosensitization. Therapeutic implication for cancer chemotherapy. Adv. Pharmacol. (1990) 21:185–220.
   Google Scholar
• ZAMORA JM, PEARSE HL, BECK WT: Physical-chemical properties shared by compounds that modulate mul-tidrug resistance in human leukemic cells. Mol. Phar-macol. (1988) 33:454–462.
   PubMed Web of Science ®Google Scholar
• SEELIG A: A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. (1998) 251:252–261.
   PubMedGoogle Scholar
• SCALA S, AKHMED N, RAO US eta].: P-glycoprotein sub-strates and antagonists cluster into two distinct groups. Mol. Pharmacol (1997) 51:1024–1033.
   Google Scholar
• SAFA AR: Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest. (1992) 10:295–305.
   Web of Science ®Google Scholar
• BECK WT, QIAN XD: Photoaffinity substrates for P-glycoprotein. Biochem. Pharmacol (1992) 43:89–93.
   PubMed Web of Science ®Google Scholar
• GREENBERGER LM, LISANTI CJ, SILVA JT, HORWITZ SB: Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdrl. I Biol. Chem. (1991) 266:20744–20751.
   Web of Science ®Google Scholar
• LOO TW, CLARKE DM Mutation of aminoacids located in predicted transmembrane domain segments 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry (1994) 33:14049–14057.
   PubMed Web of Science ®Google Scholar
• AYESH S, SHAO YM, STEIN WD: Co-operative, competi-tive and non-competitive interactions between modu-lators of P-glycoprotein. Biochim. Biophys. Acta (1996) 1316:8–18.
   PubMed Web of Science ®Google Scholar
• NIELSEN D, SKOVSGAARD T: P-glycoprotein as mul-tidrug transporter. A critical review of current mul-tidrug resistant cell lines. Biochim. Biophys. Acta (1992) 1139:169–183.
   PubMed Web of Science ®Google Scholar
• GENNE P, COUDERT B, PELLETIER H et al.: Serum con-centrations required for an in vivo modulation of an-thracycline resistance by amiodarone. Anticancer Res. (1989) 9:1655–1660.
   PubMed Web of Science ®Google Scholar
• GRUBER A, PETERSON C, REIZENSTEIN P: D-Verapamil and t-verapamil are equally effective in increasing vin-cristine accumulation in leukemic cells in vitro. Int. J. Cancer (1988) 41:224–226.
   PubMed Web of Science ®Google Scholar
• TWENTYMAN PR, BLEEHEN NM: Resistance modifica-tion by PSC-833, a novel non-immunosuppressive cy-closporin. Eur. J. Cancer (1991) 27A:1639–1642.
   Google Scholar
• GENNE P, DIMANCHE-BOITREL MT, MAUVERNAY RY etCinchonine, a potent efflux inhibitor to circum-vent anthracycline resistance in vivo. Cancer Res. (1992) 52:2797–2801.
   PubMed Web of Science ®Google Scholar
• JANSEN WJM, PINEDO HM, KUIPER CM et al.: Biochemi-cal modulation of "classical" multidrug resistance by BIB-22BS, a potent derivative of dipyridamole. Ann. Oncol. (1994) 5:733–739.
   PubMed Web of Science ®Google Scholar
• REYMANN A, LOOFT G, WOERMANN C, DIETEL M, ERTT-MANN R: Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HC1. Cancer Chemo-ther. Pharmacol (1993) 32:25–30.
   PubMed Web of Science ®Google Scholar
• DEGREGORIO MW, FORD JM, BENZ CC, WIEBE VJ: Tore-mifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J. Clin. Oncol (1989) 7:1359–1364.
   PubMed Web of Science ®Google Scholar
• SATO W, FUKAZAWA N, NAKANISHI 0 et al: Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chem other. Pharmacol (1995) 35:271–277.
   PubMed Web of Science ®Google Scholar
• PIERRE A, DUNN TA, KRAUS-BERTHIER L et al.: In vitro and in vivo circumvention of multidrug resistance by Servier-9788, a novel triazinoaminopiperidine deriva-tive. Invest. New Drugs (1992) 10:137–148.
   PubMed Web of Science ®Google Scholar
• HYAFIL F, VERGELY C, DUVIGNAUD P, GRANDPERRET T:In vitro and in vivo reversal of multidrug resistance by GF-120918, an acridone carboxamide derivative. Can-cer Res. (1993) 53:4595–4602.
   PubMed Web of Science ®Google Scholar
• GERMANN U, SHLYAKHTER D, MASON VS et al: Cellularand biochemical characterization of VX-710 as a che-mosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs (1997) 8:125–140.
   PubMed Web of Science ®Google Scholar
• LINN SC, GIACCONE G, PINEDO HM: Complete remis-sion of metastatic colorectal cancer: a pitfall in a multidrug resistance reversal trial. Lancet (1994) 343:1648–1649.
   PubMed Web of Science ®Google Scholar
• SIKIC BI: Pharmacologic approaches to reversing mul-tidrug resistance. Semin. Oncol (1997) 34\(Suppl. 5):40–47.
   Google Scholar
• MARIE JP, HUET S, FAUSSAT AM et al.: Multicentricevaluation of the MDR phenotype in leukemia. Leuke-mia (1997) 11:1086–1094.
   PubMed Web of Science ®Google Scholar
• OZOLS RF, CUNNION RE, KLECKER RW et al: Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. (1987) 5:641–647.
   PubMed Web of Science ®Google Scholar
• DURIE BGM, DALTON WS: Reversal of drug-resistance in multiple myeloma with verapamil. Br. J. Haematol (1988) 68:203–206.
   PubMed Web of Science ®Google Scholar
• DALTON WS, GROGAN TM, MELTZER PS, SCHEPER RJ,SALMON SE: Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. (1989) 7:415–424.
   PubMed Web of Science ®Google Scholar
• SALMON SE, DALTON WS, GROGAN TM et al.: Multidrug-resistant myeloma. Laboratory and clinical effects of verapamil as a chemosensitizer. Blood (1991) 78:44–50.
   Google Scholar
• MILLER TP, GROGAN TM, DALTON WS et al.: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol (1991) 9:17–24.
   PubMed Web of Science ®Google Scholar
• TRUMPER LH, HO AD, WULF G, HUNSTEIN W: Additionof verapamil to overcome multidrug resistance in mul-tiple myeloma: preliminary clinical observations in 10 patients. J. Gun. Oncol. (1989) 7:1578–1583.
   Web of Science ®Google Scholar
• MERTENS M, THOMAS L, LELIE JVD: Lack of reversalwith verapamil of drug resistance in multiple mye-loma. Br. J. Haematol. (1990) 76:155–158.
   PubMedGoogle Scholar
• DALTON WS, CROWLEY JJ, FOJO A et al.: A Phase III ran-domized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest Oncology Group study. Cancer (1995) 75:815–820.
   PubMed Web of Science ®Google Scholar
• DEMICHELI R, JIRILLO A, BONCIARELLI G et al.: 4-epidoxorubicin plus verapamil in anthracycline-refractory cancer patients. Tumouri (1989) 75:245–247.
   PubMed Web of Science ®Google Scholar
• LANGENBUCH T, MROSS K, JONAT W, HASSFELD DK: APhase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifos-famide for advanced breast cancer. Cancer Chemother. Pharmacol. (1990) 26:93–96.
   PubMedGoogle Scholar
• MROSS K, BOHN C, EDLER L et al.: Randomized Phase IIstudy of single agent epirubicin +/- verapamil in pa-tients with advanced metastatic breast cancer. Ann. Oncol. (1993) 4:45–50.
   PubMed Web of Science ®Google Scholar
• MILLWARD MJ, CANTWELL BMJ, MUNROE NC et al.: Oralverapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br. J. Can-cer (1993) 67:1031-1035. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• CAIRO MS, SIEGEL S, SENDER L: Clinical trial of continu-ous infusion verapamil, bolus vinblastine, and con-tinuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res. (1989) 49:1063–1066.
   PubMed Web of Science ®Google Scholar
• PENNOCK GD, DALTON WS, ROESKE WR et al.: Systemic toxic effects associated with high-dose verapamil infu-sion and chemotherapy administration. J. Nati Cancer Inst. (1991) 83:105–110.
   PubMed Web of Science ®Google Scholar
• BISSETT D, KERR DJ, CASSIDY J et al.: Phase Land phar-macokinetic study of n-verapamil and doxorubicin. Br. J. Cancer (1991) 64:1168–1171.
   PubMed Web of Science ®Google Scholar
• SCHEITHAUER W, KORNEK G, KASTNER J et al.: Phase IIstudy of n-verapamil and doxorubicin in patients with metastatic colorectal cancer. Eur. J. Cancer (1993) 29A:2337–2338.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, LYN P, FISCHER P et al: Phase I/II of dex-verapamil plus vinblastine for patients with advanced renal cell carcinoma. J. Clin. Oncol (1995) 13:1958–1965.
   PubMed Web of Science ®Google Scholar
• WILSON WH, BATES SE, FOJO A et al.: Controlled trial ofdexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. Clin. Oncol. (1995) 13:1995–2004.
   PubMed Web of Science ®Google Scholar
• LEHNERT M, MROSS K, SCHUELLER J et al.: Phase II trialof dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br. J. Cancer (1998) 77:1155–1163.
   PubMed Web of Science ®Google Scholar
• TOLCHER AW, COWAN KH, SOLOMON D et al.: Phase I crossover study of paclitaxel with R-verapamil in pa-tients with metastatic breast cancer. J. Clin. Oncol. (1996) 14:1173–1184.
   PubMed Web of Science ®Google Scholar
• MROSS K, HAMM K, HOSSFELD DK: Effects of verapamil on the pharmacokinetics and metabolism of epirubi-cin. Cancer Chemother. Pharmacol. (1993) 31:369–375.
   PubMed Web of Science ®Google Scholar
• MILLER RL, BUKOWSKI RM, BUDD GT et al.: Clinicalmodulation of doxorubicin resistance by the calmodu-lin inhibitor, trifluoperazine: a Phase I/II trial. J. Clin. Oncol. (1988) 6:880–888.
   PubMed Web of Science ®Google Scholar
• SRIDHAR KS, KRISHAN A, SAMY TSA et al: Phase I and pharmacokinetic studies of prochlorperazine 2-hr IV infusion as a doxorubicin-efflux blocker. Cancer Che-mother. Pharmacol. (1994) 34:377–384.
   PubMed Web of Science ®Google Scholar
• MURREN JR, DURIVAGE HJ, BUZAID AC et al: Trifluop-erazine as a modulator of multidrug resistance in re-fractory breast cancer. Cancer Chemother. Pharmacol. (1996) 38:65–70.
   PubMed Web of Science ®Google Scholar
• SONNEVELD P, DURIE BGM, LOCKHORST HM et al: Modulation of multidrug resistant multiple myeloma by cyclosporin. Lancet (1992) 340:255–259.
   PubMed Web of Science ®Google Scholar
• LIST AF, SPIER C, GREER J et al: Phase I/II trial of cyclo-sporin A as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. (1993) 11:1624–1634.
   PubMedGoogle Scholar
• VERWEIJ J, HERWEIJER H, OOSTEROM R et al: A Phase IIstudy of epidoxorubicin in colorectal cancer and the use of cyclosporin A in an attempt to reverse mul-tidrug resistance. Br. J. Cancer (1991) 64:361–364.
   PubMed Web of Science ®Google Scholar
• RODENBURG CJ, NOOTER K, HERWEIJER H et al.: Phase II study combining vinblastine and cyclosporin A to cir-cumvent multidrug resistance in renal cell cancer. Ann. Oncol. (1991) 2:305–306.
   PubMed Web of Science ®Google Scholar
• SARRIS AH, YOUNES A, MCLAUGHLIN P et al.: Cyclo-sporin A does not reverse clinical resistance to pacli-taxel in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. (1996) 14:233–239.
   PubMed Web of Science ®Google Scholar
• LUM BL, KAUBISCH S, YAHANDA AM et al: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a Phase I trial to modulate multidrug resistance. J. Clin. Oncol. (1992) 10:1635–1642.
   PubMed Web of Science ®Google Scholar
• RUSHING DA, RABER SR, RODVOLD KA et al.: The effect of cyclosporin on the pharmacokinetics of doxorubi-cin in patients with small cell lung cancer. Cancer (1994) 74:834–841.
   PubMed Web of Science ®Google Scholar
• FISCHER GA, BARTLETT NL, LUM NA et al.: Phase I trial of taxol with high-dose cyclosporin A as a modulator of multidrug resistance. Proc. Am. Soc. Clin. Oncol. (1994) 13:144. Abstract 369.
   Google Scholar
• BOOTE DJ, DENNIS IF, TWENTYMAN PR et al: Phase I study of etoposide with SDZ PSC-833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. (1996) 14:610–618.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, LINN SC, WELINK J et al.: A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC-833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. (1997) 3:2005–2015.
   PubMed Web of Science ®Google Scholar
• LEE E, GEORGE S, CALIGIURI M et al.: A Phase I study of induction chemotherapy for older patients with acute myeloid leukemia using ara-C, daunorubicin and eto-poside with and without the MDR modulator PSC-833. Blood (1997) 90\(Suppl. 1):506a. Abstract 2256.
   Google Scholar
• SONNEVELD P, MARIE JP, HUISMAN C et al.: Reversal of multidrug resistance by SDZ PSC-833, combined with VAD (vincristine, doxorubicin, dexamethasone) in re-fractory multiple myeloma. A Phase I study. Leukemia (1996) 10:1741–1750.
   PubMed Web of Science ®Google Scholar
• ADVANI R, SABA HI, TALLMAN M et al.: Treatment of poor prognosis AML with PSC-833 plus mitoxantrone, etoposide, cytarabine. Blood (1997) 90\(Suppl. 1):507a. Abstract 2260.
   Google Scholar
• KORNBLAU SM, ESTEY E, MADDEN T et al.: Phase I studyof mitoxantrone plus etoposide with multidrug block-ade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J. Clin. Oncol. (1997) 15:1796–1802.
   PubMed Web of Science ®Google Scholar
• VISANI G, MILLIGAN D, LEONI F et al.: A Phase I dose-finding study of PSC-833, a novel MDR-reversing agent, with mitoxantrone, etoposide and cytarabine in poor prognosis acute leukemia. Blood (1997) 90\(Suppl. 1):566a. Abstract 2518.
   Google Scholar
• SONNEVELD P, LOWENBERG B, VOSSEBELD P et al.: Dose-finding study of PSC-833, a novel MDR-reversing agent, with daunorubicin and ara-C, in untreated eld-erly patients with acute myeloid leukemia. Blood (1997) 90\(Suppl. 1):566a. Abstract 2517. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• FIELDS A, HOCHSTER H, RUNOWICZ C et al.: SDZ PSC- 833 / paclitaxel in paclitaxel-refractory ovarian carci-noma: a phase I trial with renewed responses. Proc. Am. Soc. Clin. Oncol. (1997) 16: 351a. Abstract #1254.
   Google Scholar
• KRISTENSEN G, BAEKELANDT M, HOLM R et al.: Evalua-tion of PSC-833 in combination with doxorubicin/cis-platin in refractory ovarian cancer. Anticancer Drugs (1994) 5 (Suppl. 0:64. Abstract 147.
   Google Scholar
• LUSH RM, MEADOWS B, FOJO AT et al.: Initial pharma-cokinetics and bioavailability of PSC-833, a P-glycoprotein antagonist. J. Clin. Pharmacol. (1997) 37:123–128.
   PubMed Web of Science ®Google Scholar
• WISHART CC, BISSETT D, PAUL J et al.: Quinidine as a re-sistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled ran-domized trial. J. Gun. Oncol. (1994) 12:1271–1277.
   Google Scholar
• SOLARY E, CAILLOT D, CHAUFFERT B et al.: Feasibility of using quinine, a potential multidrug resistance revers-ing agent, in combination with mitoxantrone and cy-tarabine for the treatment of acute leukemia. J. Clin. Oncol. (1992) 10:1730–1736.
   PubMed Web of Science ®Google Scholar
• SOLARY E, WITZ B, CAILLOT D et al.: Combination ofquinine as a potential reversing agent with mitoxan-trone and cytarabine for the treatment of acute leuke-mias: a randomized multicenter study. Blood (1996) 88:1198–1205.
   PubMed Web of Science ®Google Scholar
• MILLER TP, CHASE EM, DORR R et al.: A Phase I/II trial ofpaclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anti-cancer Drugs (1998) 9:135–140.
   PubMed Web of Science ®Google Scholar
• GENNE P, CAILLOT D, CASASNOVAS RO et al: MDR re-versing activity of serum from patients treated with cinchonine. Proc. Am. Assoc. Cancer Res. (1997) 38:593-594. Abstract 3987.
   Google Scholar
• TRUMP DL, SMITH DC, ELLIS PG et al.: High-dose oral ta-moxifen, a potential multidrug-resistance reversal agent. Phase I trial in combination with vinblastine. J. Nat. Cancer Inst. (1992) 84:1811–1816.
   PubMed Web of Science ®Google Scholar
• SMITH DC, TRUMP DL: A Phase I trial of high-dose oral tamoxifen and COPE. Cancer Chemother. Pharmacol. (1995) 36:65–68.
   PubMed Web of Science ®Google Scholar
• MILLWARD MJ, CANTWELL BM., LIEN EA, CARMICHAEL J, HARRIS AL: Intermittent high-dose tamoxifen as a po-tential modifier of multidrug resistance. Eur. J. Cancer (1992) 28A:805–810.
   PubMed Web of Science ®Google Scholar
• CHRISTEN RD, MCCLAY EF, PLAXE SC eta].: Phase I/phar-macokinetic study of high-dose progesterone and doxorubicin. j Clin. Oncol. (1993) 11:2417–2426.
   Google Scholar
• VAN KALKEN CK, VAN DER HOE VEN JJM, DE JONG J et al.: Bepridil in combination with anthracyclines to re-verse anthracycline resistance in cancer patients. Eur. J. Cancer (1991) 27A:739–744.
   Google Scholar
• BATES SE, MEADOWS B, GOLDSPIEL BL et al.: A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. Cancer Chemo-ther. Pharmacol (1995) 35:457–463.
   PubMed Web of Science ®Google Scholar
• MURPHY BR, RYNARD SM, PENNINGTON KL, GROSH W,LOEHRER PJ: A Phase II trial of vinblastine plus dipyri-damole in advanced renal cell carcinoma. Am. J. Clin. Oncol. 17:10–13.
   Google Scholar
• PUNT CJA, VOEST EE, TUENI E et al.: Phase IB study ofdoxorubicin in combination with the multidrug resis-tance reversing agent S-9788 in advanced colorectal and renal cell cancer. Br. J. Cancer (1997) 76:1376–1381.
   PubMed Web of Science ®Google Scholar
• PECK RA, MARSHALL J, ZIESSMAN H eta].: A Phase I trialof doxorubicin and VX-710. Proc. Am. Assoc. Cancer Res. (1996) 37:165 Abstract 1134.
   Google Scholar
• SMITH L, ROWINSKY E, CHATURVEDI P et al: Pharma-cokinetic and toxicologic interactions between the multidrug resistance reversal agent VX-710 and pacli-taxel in cancer patients. Proc. Am. Soc. Clin. Oncol. (1997) 16:218a. Abstract 764.
   Google Scholar
• MICKISCH GH, MERLINO GT, GALSKI H, GOTTESMAN MM, PASTAN I: Transgenic mice that express the hu-man multidrug resistance gene in bone marrow en-able a rapid identification of agents that reverse drug resistance. Proc. Natl Acad. Sci. USA (1991) 88:547–551.
   PubMed Web of Science ®Google Scholar
• MECHETNER EB, RONINSON IB: Efficient inhibition ofP-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad. Sci. USA (1992) 89:5824–5828.
   PubMed Web of Science ®Google Scholar
• ALAHARI SK, DEAN NM, FISCHER MH et al.: Inhibition ofexpression of the multidrug resistance-associated P-glycoprotein by phosphorothiate and 5' cholesterol-conjugated phosphorothiate antisense oligonucleo-tides. Mol. Pharmacol. (1996) 50:808–819.
   PubMed Web of Science ®Google Scholar
• BARRAND MA, RHODES T, CENTER MS, TWENTYMAN PR:Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190 kDa mem-brane protein distinct from P-glycoprotein. Eur. J. Can-cer (1993) 29A:408–415.
   PubMed Web of Science ®Google Scholar
• LACRETA FP, BRFENNAN JM, NASH SL eta].: Pharmacoki-netics and bioavailability of athacrynic acid as a modu-lator of drug resistance in patients with cancer. J. Pharmacol. Exp. Ther. (1994) 270:1186–1191.
   Google Scholar
• BAILEY HH, RIPPLE G, TUTSCH KD etal.: Phase I study of continuous infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J. Natl. Cancer Inst. (1997) 89:1789–1796.
   Google Scholar
• SCHRODER CP, GODWIN AK, O'DWYER PJ et al: Glu-tathione and drug resistance. Cancer Invest. (1996) 14:158–168.
   PubMed Web of Science ®Google Scholar
• ROBERT J: Proposals for concomitant use of several modulators of multidrug resistance in clinics. Antican-cer Res. (1994) 14:2371–2374.
   PubMed Web of Science ®Google Scholar